
Normal
Tumor
HFF
HCT116
MRC5
MDA-MB-231
WI-38
U87
Cell Viability
100.0%
75.0%
50.0%
25.0%
0.0%
0.1
1
10
100
Compound (1) (μM)
Doxorubicin

FIG. 1


125%
100%
75%
50%
Cell Viability
DMSO
0
24
48
72
Time from Compound (1) Removal (hrs)

FIG. 2


DRD1
DRD2L
DRD2S
DRD3
DRD4
DRD5
% Antagonism
100
75
50
25
0
-25
-50
0.001
0.01
0.1
1
10
100
ONC201 (microM)

FIG. 3


Baseline
Max Response
Prolactin (ng/mL)
80.000
70.000
60.000
50.000
40.000
30.000
20.000
10.000
0.000
1
2
3
4
5
6
7
8
9
10
11
Patient

FIG. 4


10000
1000
100
10
1
0.1
Concentration (ng/mL)
0
24
48
72
96
120
144
168
Time (hours)
125 mg (n = 1)
250 mg (n = 1)
375 mg (n = 1)
500 mg (n = 1)
625 mg (n = 6)
Assay LLOQ

FIG. 5A


10000
1000
100
10
1
Concentration (ng/mL)
0
24
48
72
96
120
144
168
Time (hours)

FIG. 5B


AUC vs Dose
Regression
Dose Proportional*
AUC (h.ng/mL)
60000
50000
40000
30000
20000
10000
0
100
200
300
400
500
600
700
Dose (mg)

FIG. 6A


Cmax vs Dose
Regression
Dose Proportional*
Cmax (ng/mL)
8000
6000
4000
2000
0
100
200
300
400
500
600
700
Dose (mg)

FIG. 6B


M30 Assay Ratio
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
Pat #7
Pat #5
Pat #3
Pat #6
0 hrs
6 hrs
24 hrs
48 hrs
Day 7
Day 21
Day 43
Time After First Dose

FIG. 7A


M30 Assay Ratio
4
3
2
1
0
21 Day
6 hr
7 Day
21 Day
21 Day
6 hr
50% Increase Over Baseline
#3 (uterine) (375 mg)
#4 (Renal) (500 mg)
#6 (Prostate) (625 mg)
#7 (Lung) (625 mg)
#8 (Colon) (625 mg)
#9 (Spindle Cell Sarcoma)

FIG. 7B


Low
Relative Sensitivity
High
1200
1000
800
600
400
200
0
Lymphoma 69
Testes 3
Intestine (CRC) 47
Prostate 10
Lung SCLC 63
Stomach 29
Nervous System 36
Liver 20
Vulva 5
Pleura 24
Brain 58
LUNG : NSCLC 112
Thyroid 18
Skin (Melanoma) 55
Ovary 48
Head & Neck 44
Kidney 36
Miscellaneous 11
Uterus 19
Urinary Track 22
Cervix 14
Pancreas 33
Bone 36
Leukemia 103
Breast 56
Muscle 9
Biliary Tract 6
Esophagus 34

FIG. 8